Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
NCT05900089Phase 1Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivarmacitinib in peripheral T-cell lymphoma (PTCL) and natural killer cell lymphoma (3 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Recommended Phase 2 Dose and Adverse Events. Planned start May 2023; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer cell lymphoma
Beyond the preview
Go deeper on NCT05900089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900089.